NCT02656498已完成2 期
An Open Label, Multicenter Study for Evaluation of the Clinical Utility of [18F]THK-5351 Positron Emission Computed Tomography in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, Subjects With Alzheimer's Disease and Subjects With Other Neurodegenerative Diseases
Jae Seung Kim2 个研究点 分布在 1 个国家目标入组 135 人开始时间: 2016年1月11日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 135
- 试验地点
- 2
- 主要终点
- Cross-sectional [18F]THK-5351 Imaging Results
研究概览
简要总结
This is a cross-sectional and longitudinal study to evaluate the clinical utility of [18F]THK-5351 positron emission computed tomography in cognitively healthy volunteers, mild cognitive impairment (MCI), Alzheimer's disease (AD) and other neurodegenerative patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •General Subject Inclusion Criteria
- •In order to be eligible for participation in this trial, the subject must:
- •Be ≥ 40 and < 80 years of age at the Screening Visit.
- •Be able to read at a 6th grade level or equivalent, (as determined by the investigator, and must have a history of academic achievement and/or employment sufficient to exclude mental retardation.)
- •Be able to speak, read, hear, and understand the language of the trial staff, and the informed consent form, and possess the ability to respond verbally to questions, follow instructions, and complete questionnaires and detailed neuropsychological test.
- •Have results of clinical laboratory tests/physical examination, vital signs, and ECG within normal limits (at 90 days prior to [18F]THK-5351 positron emission computed tomography) or clinically acceptable to the investigator at screening.
- •Be able to possess the ability to respond verbally to questions, follow instructions, and underwent research assessment, including brain images based on the investigator's judgment. Each subject is also able and willing to adhere visit schedules.
- •If female, not be of childbearing potential as indicated by one of the following
- •Each subject (or legal representative) must sign the informed consent form in accordance with local requirements after the scope and nature of the investigation have been explained to them, and before screening assessments.
- •Each subject must be willing to provided blood samples for genotyping apolipoprotein E
- •Cognitively Healthy Subjects
- •MCI Subjects
- •AD Subjects
- •Subjects with other neurodegenerative disease
- •Exclusion Criteria
- •The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below:
- •General Exclusion Criteria
- •Based on the investigators' judgement, if the patient is not capable of communicating with the site personnel, if the patient is not proficient in the language in which the psychometric tests will be completed, or if the patient is not sufficient for compliance with the study procedures.
- •The patient has an abnormal physical examination or abnormal laboratory test results at the screening that are clinically significant to affect results of the research, as judged by the investigator.
- •If the patient has or is suspicious of having a hypersensitivity or allergy to [18F] THK-5351 or its derivatives.
- •The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) children.
- •The patient has a history of alcoholism or drug dependency/abuse within the last 2 years before screening.
- •The patient has contraindications to undergo positron emission computed tomography or MRI, which include but are not restricted to the examples below: claustrophobia, cardiac pacemaker, metal devices around the eye or spinal cord, cochlear implant, etc.) at the screening visit.
- •The patient has been treated with any investigational medicinal product (IMP) within 30 days prior to the screening visit.
- •The patient has been tested positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), HIV Antibody, or syphilis serum test at the screening visit.
- •The patient has been receiving an anti-cholinergic drug in a regular basis within 3 months prior to the screening visit.
- •The patient has evidence of a clinically relevant neurological disorders other than the disease being studied (i.e., prodromal AD) at screening, including but not limited to: territorial cerebral infarction, intracranial hemorrhage, multiple sclerosis, neurosyphilis, mental retardation, hypoxic encephalopathy, major head trauma with loss of consciousness that led to persistent cognitive deficits.
排除标准
- 未提供
研究组 & 干预措施
Cognitively Healthy Subjects
Experimental
Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
干预措施: [18F]THK-5351 (Drug)
MCI Subjects
Experimental
MCI Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
干预措施: [18F]THK-5351 (Drug)
AD Subjects
Experimental
AD Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
干预措施: [18F]THK-5351 (Drug)
Subjects with other neurodegenerative disease
Experimental
Subjects with other neurodegenerative disease will receive an IV injection, [18F]THK-5351 at baseline.
干预措施: [18F]THK-5351 (Drug)
结局指标
主要结局
Cross-sectional [18F]THK-5351 Imaging Results
时间窗: 50-70 minutes post injection
Compare Standard uptake value ratio (SUVR) and distribution of \[18F\]THK-5351 in subjects with MCI, subjects with AD, subjects with other neurodegenerative disease and cognitively healthy individuals.
Assess the rate of change of tau deposition as measured by [18F]THK-5351 uptake (SUVR) over time
时间窗: 24 months
Compare Standard uptake value ratio (SUVR) and distribution of \[18F\]THK-5351 in subjects with MCI, subjects with AD, subjects with other neurodegenerative disease and cognitively healthy individuals.
次要结局
- Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and neuropsychiatric test scores(50-70 minutes post-injection)
- Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of structural MRI(50-70 minutes post-injection)
- Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of functional MRI(50-70 minutes post-injection)
- Correlation between standard uptake value ratios (SUVR) and distribution of [18F]THK-5351 positron emission computed tomography and amyloid positron emission computed tomography(50-70 minutes post-injection)
研究者
Jae Seung Kim
Professor
Asan Medical Center
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerFallopian Tube CancerPeritoneal CancerOvarian CancerNCT06735326Qilu Hospital of Shandong University105
招募中
不适用
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOnType B Aortic DissectionNCT06675617Intressa Vascular SA72
已完成
2 期
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic DermatitisModerate to Severe Atopic DermatitisNCT06012812Shanghai Hengrui Pharmaceutical Co., Ltd.79
已完成
4 期
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyRelapsed and/or Refractory Multiple MyelomaNCT03416374Takeda45
已完成
不适用
Investigation of Preservative-Free Ophthalmic Solution in Ocular DrynessDry Eye SyndromesNCT05778942SIFI SpA35